✦ LIBER ✦

Exploring and validating surrogate endpoints in colorectal cancer

✍ Scribed by Tomasz Burzykowski; Marc Buyse; Greg Yothers; Junichi Sakamoto; Dan Sargent

Book ID: 106451438
Publisher: Springer
Year: 2008
Tongue: English
Weight: 328 KB
Volume: 14
Category: Article
ISSN: 1380-7870
DOI: 10.1007/s10985-007-9079-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Intraepithelial neoplasia, surrogate end

Intraepithelial neoplasia, surrogate endpoint biomarkers, and cancer chemoprevention

✍ Dr. Charles W. Boone; Gary J. Kelloff 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 930 KB

Neoplasia is a progression of molecular, cellular, and tissue changes starting with a critical cell mutation and advancing by clonal evolution, involving further multiple mutations and expanding mutated clones. This process is characterized by five general stages: latency, focal growth of normal-app

Cervical cancer chemoprevention, vaccine

Cervical cancer chemoprevention, vaccines, and surrogate endpoint biomarkers

✍ Michele Follen; Frank L. Meyskens Jr.; Ronald D. Alvarez; Joan L. Walker; Maria 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 883 KB

At the Second International Conference on Cervical Cancer, held April 11-14, 2002, experts in cervical cancer prevention, detection, and treatment reviewed the need for more research in chemoprevention, including prophylactic and therapeutic vaccines, immunomodulators, peptides, and surrogate endpoi

FDA and surrogate endpoints in Alzheimer

FDA and surrogate endpoints in Alzheimer's disease

✍ Osborne, Randy 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 56 KB

Validation of Surrogate Endpoints in Mul

Validation of Surrogate Endpoints in Multiple Randomized Clinical Trials with Discrete Outcomes

✍ Didier Renard; Helena Geys; Geert Molenberghs; Tomasz Burzykowski; Marc Buyse 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 129 KB 👁 1 views

A phase II chemoprevention trial design

A phase II chemoprevention trial design to identify surrogate surrogate endpoint biomarkers in breast cancer

✍ Kapil Dhingra 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 434 KB

Surrogate biomarkers for risk assessment and efficacy of potential chemopreventive agents are needed to improve the efficiency and reduce the cost of conducting chemoprevention trials. In addition to criteria of sensitivity, specificity, quantifiability, and reproducibility applicable to most potent

Meta-analysis for the evaluation of surr

Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials

✍ Qian Shi; Daniel J. Sargent 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 254 KB